JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Serum collagen IV as a predictor for response to direct-acting antivirals hepatitis C therapy

  • 0Chemistry Department, Faculty of Science, Port Said University, Port Said, Egypt.
Journal of Immunoassay & Immunochemistry +

|

October 15, 2024

|

October 15, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Baseline serum collagen IV levels can predict treatment failure in chronic hepatitis C (CHC) patients receiving direct-acting antiviral (DAA) therapy. Higher collagen IV indicates a lower chance of sustained virological response (SVR).

Area Of Science

  • Hepatology and Viral Gastroenterology
  • Biomarker Discovery in Infectious Diseases
  • Pharmacogenomics and Treatment Response

Background

  • Direct-acting antiviral (DAA) therapies have significantly improved chronic hepatitis C (CHC) treatment effectiveness.
  • However, a subset of patients do not achieve sustained virological response (SVR), necessitating identification of predictive factors.
  • Understanding treatment failure predictors is crucial for optimizing CHC management strategies.

Purpose Of The Study

  • To investigate the association between baseline serum collagen IV levels and DAA treatment failure in Egyptian CHC patients.
  • To assess the predictive capability of collagen IV for treatment response to sofosbuvir/daclatasvir therapy.

Main Methods

  • A cohort of 175 CHC patients (100 responders, 75 non-responders) undergoing sofosbuvir/daclatasvir treatment were analyzed.
  • Serum collagen IV was quantified using a sensitive chemiluminescent immunoassay.
  • Statistical analyses, including ROC curve analysis, were performed to evaluate collagen IV's predictive performance.

Main Results

  • Non-responders exhibited significantly higher median baseline serum collagen IV levels (19.02 µg/L) compared to responders (9.7 µg/L) (P < 0.0001).
  • Collagen IV demonstrated strong discriminatory ability for non-responders (AUC = 0.890), with 92% sensitivity and 72% specificity.
  • Elevated collagen IV levels correlated with decreased albumin, and increased APRI and FIB-4 scores.

Conclusions

  • Baseline serum collagen IV is a significant predictor of DAA treatment response in CHC patients.
  • Measurement of collagen IV may aid in personalizing treatment duration and improving disease control strategies.
  • Further research is warranted to validate these findings and integrate collagen IV into clinical practice.

Keywords: